Skip to main content

Table 1 Characteristics of study population

From: The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients

Total 47
Age, years, median (range)  
at onset 30 (11–67)
at initiation of tacrolimus 40 (12–70)
Disease duration, months, median (range) 43.6 (0.74-336)
Gender  
Male 24 (51%)
Female 23 (49%)
Disease severity  
Moderate 34 (72%)
Severe 13 (28%)
Extent of disease  
Pancolitis 34 (72%)
Left-side colitis 13 (28%)
Concomitant therapy  
5-ASA 42 (89%)
Corticosteroid use 42 (89%)
Immunomodulator use 13 (28%)
SNPs analysis  
CYP3A5 (*1*1/*1*3/*3*3) 1/12/24
ABCB1 exon26 (CC/CT/TT) 15/14/8
  1. The SNP analysis was performed only for patients who provided written informed consent for this procedure.
  2. SNPs, single-nucleotide polymorphisms 5-ASA, 5-aminosalicylic acid.
  3. CYP3A5, cytochrome P450 3A4.
  4. ABCB1, ATP-binding cassette sub-family B member 1.